Proactive Investors - Run By Investors For Investors

Winner is 32 Red, Even, 3rd dozen, high

Winner is 32 Red, Even, 3rd dozen, high

32RED (LON:TTR 131.25p/£109.83m)
32Red, the online gaming operator, announced a three year agreement to sponsor Leeds United Football Club, commencing in the 2016/17 season. The agreement provides 32Red with shirt sponsorship, access to Leeds United's global fan base and extensive brand visibility throughout the club's iconic Elland Road stadium as well as across its digital and media platforms. 32Red's trading during 2016 has remained very strong across the Group's portfolio.  The Company's like-for-like net gaming revenues for the first nineteen weeks of the year to 11 May 2016 is up 39 percent on the same period in 2015 and up 71 percent including the contribution from Roxy Palace. The Board remains confident of delivering its expectations for the year.

7digital Group (LON:7DIG 7.25p/£8.84m)
7digital, the B2B digital music and radio services company, announced it has signed a contract with musical.ly, a fast-growing social media platform based around video and music with a strong international footprint. The deal will contribute to 7digital's revenues for 2016. 7digital also updated that its client i.am+, the technology company founded by musician and entrepreneur will.i.am, has announced it is now taking pre-orders in the UK for the Dial wearable 'smartcuff' device ahead of its launch on 13 May. The Dial's innovative model allows access to millions of tracks without the need for any additional subscription.

Ace Liberty and Stone (LON:ALSP 4p/ £39.3m)*
Ace Liberty and Stone, the active property investment company capitalising on commercial property investment opportunities across the UK, announced that Dr Anthony Ghorayeb, currently Non-Executive Director of Ace, assumes the role of Non-Executive Chairman with immediate effect. Dr Ghorayeb is also currently the Executive Chairman and co-founder of LiBank, the Lebanese investment bank offering services tailored to high-net-worth individuals (HNWIs), and the Secretary General of the Levant Business Union. Keith Pankhurst, currently Non-Executive Chairman, assumes the role of Senior Independent Director.

Clinigen Group (LON:CLIN 546.00p/ £625.56m)
Clinigen Group, the global pharmaceutical and services company, and Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, have signed an exclusive agreement to commercialise the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year. Ethyol is an FDA approved cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.  This is Cumberland's first oncology support product and is a good complement to its portfolio of specialty pharmaceuticals. Under the terms of the agreement, Cumberland will be responsible for all marketing, promotion, and distribution of the product in the U.S. Clinigen acquired the worldwide rights to Ethyol from AstraZeneca in 2014, and this is an important step in the revitalisation plan for the product. 

Cyprotex (LON:CRX 106.50p/£23.38m)
Cyprotex, a specialist Contract Research Organisation, announced the launch of version 2 of its in silico modelling solution, chemPKTM, which predicts human pharmacokinetics directly from chemical structure. Pharmacokinetics is defined as the study of the concentration of a drug or chemical in the body over time, and is related to its absorption, distribution, metabolism and excretion. Understanding the pharmacokinetics is important for understanding the efficacy (effectiveness) or potential toxicity of drugs or chemicals following their administration. The original version of chemPKTM was able to predict human pharmacokinetics following administration of a single oral dose. Version 2 now has the ability to predict human pharmacokinetics following administration of both oral and intravenous dose. It is also able to simulate repeat-dose administration and so is more relevant to the typical dosing regimen within the clinic. Unlike most competing products, chemPKTM uses a PBPK (physiologically-based pharmacokinetic) modelling approach which is a more robust technique for this purpose. The software is easy to implement and use. It operates on the freely available KNIME Analytics Platform for workflow management which facilitates integration with a wide range of other cheminformatics, analytics and modelling tools.

Deltex Medical (LON:DEMG 3.88p/£10.28m)
Deltex Medical, the global leader in oesophageal Doppler monitoring, announced that it has added two additional hospital accounts to its platform programme in the USA. The first account is a sister hospital of one of our longest established platform accounts. Deltex responded to increased interest from the additional account in 2015 by allocating clinical support within its dedicated trainer programme. Since then, probe sales have grown steadily and are now running at over 50 probes a month. This account becomes the fifth platform account in the Company's West Coast territory.  The second account comprises two linked facilities in Oklahoma and is the second remote trainer platform account, which the Company is supporting out of its Mid-West territory, with occasional on-site training to supplement the Company's e-learning programmes. The account is the fourth platform account in the territory and is currently using around 35 to 40 probes a month which it expects to increase as it expands its adoption of enhanced recovery surgical programmes.

Dillistone Group (LON:DSG 17.17p/£17.17m)
Dillistone Group, the supplier of executive recruitment software, announced that its Voyager Software division has signed a development partnership with one of the UK's ten largest recruitment companies (the Partner). Through the collaboration, the Division will work closely with the Partner to further optimise a new product which will be launched this year.  The Division will retain all intellectual property relating to the new solution.  As part of the contract, the Partner will pay a significant five figure fee to the Division, and will receive discounted rates on post launch licensing.

GLI Finance (LON:GLIF 29.75p/£90.62m)
GLI, an alternative finance provider to small and medium sized enterprises,  announced that the Company has entered into conditional share sale and purchase agreements in respect of the acquisition by the Company of certain interests in entities within the Sancus and BMS sub-groups of the Company (the Acquisitions).  The move follows a strategic review of the Company's operations initiated by the Company's new CEO Andy Whelan in December 2015. Following completion, the combined Sancus BMS Group is expected to make pre-tax profit of approximately £2.5m in 2016, rising to approximately £4m in 2017 when loan books are fully deployed, the businesses are fully integrated and increasing levels of commercial, operating and financial synergies are realised.  The Board also sees potential for the Sancus BMS Group in terms of generating free cash flow to service future dividend payments to the Company's Ordinary Shareholders, with this free cash flow to be paid up to the Company.

Horizon Discovery Group (LON:HZD 177.00p/£164.79m) 
Horizon Discovery Group, the application of gene editing technologies company, announced it has entered into two Original Equipment Manufacture agreements with a global market leading Next Generation Sequencing platform company, with the potential for additional agreements to follow. Horizon is a leading provider of highly characterised genetic materials that are used as reference standards for the development and quality control of molecular assays.  These reference standards help laboratories to establish and validate their workflows. Under the terms of the agreements, Horizon will supply two previously developed HDx™ Molecular Reference Standards that cover many of the genes most commonly linked with cancer progression and response to treatment.  The Horizon materials will be incorporated into assay kits from the NGS manufacturer for a range of applications including cancer research and diagnostics.

LiDCO (LON:LID 7.26p/£14.56m)
LiDCO, the hemodynamic monitoring company, announced it has signed a distribution agreement with its partner ICU Medical, Inc. to sell the LiDCO IM non-invasive hemodynamic monitoring system in the United States. LiDCO IM is a specially configured hemodynamic monitor produced exclusively for ICU Medical that works solely in conjunction with LiDCO's non-invasive module. LiDCO and ICU Medical have an existing royalty agreement allowing ICU Medical to incorporate LiDCO's technology into its FDA 510(k)-cleared CogentTM 2-in-1 hemodynamic system, which combines both invasive and minimally invasive hemodynamic monitoring capability on a single platform. Both the Cogent in minimally invasive mode and the LiDCO IM non-invasive monitor use the LiDCO PulseCOTM algorithm to determine cardiac output and stroke volume, allowing continuity of measurement across patient acuity levels. ICU Medical announced on its Q1 2016 earnings call that the company plans further refinements of the Cogent system in advance of a full market release. Availability of the non invasive LiDCO IM system is anticipated for Q3 2016.

MediaZest (LON:MDZ 0.135p/£1.56m)*
MediaZest, the creative audio-visual company, announced that it has raised £0.25m through an oversubscribed placing and that, in addition, it will issue new Ordinary Shares to City and Claremont Capital Assets Ltd following the conversion of loan interest amounting to £50,000, in each case at a price of 0.15p per Ordinary Share. The Issue Price is the price that the market bid price was at closing on 10 May 2016. The Group has made significant progress over the last 12 months and finished the year ended 31 March 2016 with its best ever financial performance. The net funds raised will be used to help deliver current and future projects for existing clients including Hyundai, Adidas, HMV, Diesel and Kuoni. The funds will also provide MediaZest with additional working capital and will help the Company to develop new business opportunities and expand the client base as it looks to build upon recent success and implement its key growth strategy of building a more consistent and recurring income base. In addition, the conversion of £50,000 of outstanding interest will further reduce the amount of shareholder debt owed by the Company and strengthen the balance sheet.

Sareum (LON:SAR 0.885p/£23.56m)*
Sareum Holdings, the specialist cancer drug discovery and development company, announced the appointment of Dr Stephen Parker as Non-executive Chairman of the Company. Dr Stephen Parker succeeds Dr Paul Harper with immediate effect. Dr Stephen Barry Parker, aged 57, is Chairman of Silence Therapeutics PLC.  His career in the healthcare and pharma sector spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences.

Seeing Machines (LON:SEE 4.00p/£41.85m)
Seeing Machines Limited, the vehicle operator monitoring technology company, announced that it has signed a term sheet with a US-based investment firm with extensive experience in automotive technologies, for investment into a separately funded company solely focused on commercialising Seeing Machines' technology in the automotive market.  Seeing Machines would retain a significant equity stake in the new company. The term sheet is non-binding, except for customary legal obligations and due diligence. Seeing Machines and its advisors are working with the lead investor and other investors to finalise the investment round.

Synety Group (LON:SNTY 70.50p/£9.79m) 
SYNETY, a cloud-based software and communications company, announced that, following a successful pilot, its key partner, Bullhorn, has chosen to use the full CloudCall service for its own internal use across Bullhorn's EMEA operations. CloudCall integrates real-time communications capabilities into cloud-based CRM systems, bridging the gap between CRM software and real-time communications. This results in completely seamless interactions between the disparate technologies. By adopting to use CloudCall, Bullhorn's staff who use Bullhorn's own CRM system to manage their activities and customer interactions will be able to benefit from increased efficiency and ease of communications that CloudCall provides.

Ten Alps (LON:TAL 1.17p/£5.12m) 
Ten Alps, trading as Zinc Media, the TV and multimedia content producer, provided the following update on trading. Whilst the Company does not yet have total visibility on its full year results, the Directors believe that the Company will fall materially behind market expectations for the year ending June 2016. The Group has continued to sustain losses in certain parts of its publishing operations, the turnaround of which has taken longer than expected. These continued losses are likely to result in the Group not being profitable for the year as a whole, albeit the Directors do expect some improvement on the losses recorded in FY15. The Company is in advanced stages of discussion on the disposal of certain areas of its publishing business and action is being taken to restructure and refocus the remaining parts of the division. The Group's television and communications businesses are operating profitably, however the television division was impacted by delays in commissioning, which affected the entire industry. Reef, the Group's recent acquisition, is trading well.

Versarien (LON:VRS 13.75p/£14.52m)
Versarien, the advanced engineering materials group announced it has entered into a Memorandum of Understanding with Bromley Technologies Ltd to collaborate on the development of graphene enhanced carbon fibre products using Versarien's graphene nano platelets. Bromley Technologies, founded in 2000 by Dr Kristan Bromley, four time Olympian and World Champion Skeleton racer, is focussed on developing and marketing innovative, game changing products and technologies, particularly in the action sports domain.  Bromley Technologies has particular expertise in carbon fibre composite structures and it is intended that Versarien will collaborate in the design and testing of a wide variety of graphene enhanced composite structures, using Versarien's patented process. The initial focus is expected to be on products in the elite sports area, where the early adoption of new technology to gain a performance advantage is common place. These products are also expected to showcase the use of graphene in carbon fibre composite structures more widely.

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

 

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use